Does evantuzumab/Carestream have any effect on the heart?

Amivantamab is a new type of anti-cancer drug that effectively controls the growth of non-small cell lung cancer (NSCLC) and other malignant tumors by dual-targeting the EGFR and MET signaling pathways. However, as a chemotherapy drug, evantumumab may have some effects on heart health.

Clinical studies have shown that the use of evantumumab may be associated with certain adverse cardiac effects, particularly in some patients with pre-existing heart disease. The most common cardiac side effects include tachycardia, heart failure, and more. Although these cardiac adverse effects are rare, patients receiving evantumumab, especially those with a history of heart disease, should pay special attention to their heart health.

For patients receiving evantumumab, especially those with pre-existing heart disease (such as heart failure, hypertension, etc.), regular evaluation of cardiac function is very important. During treatment, patients need to be closely monitored for any possible cardiac discomfort, such as chest pain, shortness of breath, palpitations, and other symptoms. If serious cardiac side effects occur, treatment may need to be paused or modified.

Although evantumumab carries some risk of heart-related side effects, most patients do not develop significant heart problems while taking the drug. Doctors usually consider the benefits and risks of drugs based on the patient's specific situation and arrange treatment reasonably. Overall, evantumumab can effectively reduce the risk of adverse cardiac effects in the right patient population and with appropriate monitoring.

When used correctly and with close health monitoring, evantumumab can provide significant therapeutic benefits to patients, especially those with advanced NSCLC who are refractory to traditional treatments.

Reference materials:https://www.rybrevant.com/